Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00648986 · ClinicalTrials.gov registry record · Phase 4

Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails

A Phase 4 study, sponsored by Columbia University.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target

NCT00648986 is a Phase 4 study that has completed, run by Columbia University. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00648986, a Phase 4 study, has completed, sponsored by Columbia University.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether topical tazarotene (Tazorac), a receptor-selective synthetic retinoid that normalizes epidermal differentiation, ameliorates signs and symptoms of brittle nails.

Interventions

  • DRUG Tazorac

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2005-08
Est. Completion 2006-12
Phase Phase 4

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT00648986

The ClinicalTrials.gov registry entry for NCT00648986 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Tazorac is the first listed.

NCT00648986 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00648986 about?

NCT00648986 is a clinical study titled "Efficacy and Safety Study of Tazarotene (Tazorac) for the Treatment of Brittle Nails". The purpose of this study is to determine whether topical tazarotene (Tazorac), a receptor-selective synthetic retinoid that normalizes epidermal differentiation, ameliorates signs and symptoms of brittle nails.

What is the current status of trial NCT00648986?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2005-08. Estimated completion is 2006-12.

What interventions are being tested in trial NCT00648986?

The interventions under investigation include: Tazorac (DRUG).

Who is sponsoring clinical trial NCT00648986?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.